Pharmaxis Ltd (PXS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12406
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company provides products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lung function and relieves the mucus burden in the lungs of patients. It offers products pipeline such as orbital dry powder inhaler, PXS-4728A, LOXL-2 and ASM8. Pharmaxis provides solutions for cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease, and inflammatory and fibrotic diseases such as nonalcoholic steatohepatitis and pulmonary fibrosis, among others. The company operates in Australia. Pharmaxis is headquartered in Sydney, New South Wales, Australia.

Pharmaxis Ltd (PXS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 11
Pharmaxis Expands Agreement with Synairgen 12
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 13
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 14
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 15
Equity Offering 16
Pharmaxis to Raise USD17.7 Million in Private Placement of Shares 16
Pharmaxis Announces Second Tranche Of Private Placement Of Shares For US$20 Million 18
Asset Transactions 19
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 19
Pharmaxis Ltd – Key Competitors 21
Pharmaxis Ltd – Key Employees 22
Pharmaxis Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 24
Corporate Communications 25
Oct 04, 2018: Pharmaxis non executive director dr Simon Buckingham to retire at 2018 annual general meeting 25
Sep 18, 2018: Pharmaxis names Edward Rayner as Board Director 26
Oct 19, 2017: Pharmaxis Strengthens Drug Discovery Capability as its Technology Platform Continues to Deliver 27
Jun 07, 2017: Pharmaxis Appoints Former Head of Global Research at Merck to Board of Directors 28
Product News 29
Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 29
Clinical Trials 30
Nov 20, 2018: Pharmaxis anti-fibrotic LOX inhibitor program for pancreatic cancer ready to commence phase 1 clinical trials 30
Nov 15, 2018: Arix Bioscience: Pharmaxis releases positive results of phase 1 clinical trial for Second LOXL2 inhibitor compound 31
Oct 11, 2018: Pharmaxis releases positive results of phase 1 clinical trial for LOXL2 inhibitor compound 32
Jun 14, 2018: Pharmaxis “Best in Class” LOXL2 Program Attracts Strong Pharma Interest as it Enters Final Stages of Phase 1 Trials 33
Jun 14, 2018: Pharmaxis ‘Best In Class’ LOXL2 Program Attracts Strong Pharma Interest As It Enters Final Stage Of Phase 1 Trials 34
Sep 06, 2017: Pharmaxis Announces Anti Fibrotic LOXL2 Program Clears Preclinical Development And Set To Commence Phase 1 Trials 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharmaxis Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharmaxis Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 12
Pharmaxis Expands Agreement with Synairgen 13
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 14
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 15
Pharmaxis Enters Into Distribution Agreement With PharmaSwiss For Bronchitol 16
Pharmaxis to Raise USD17.7 Million in Private Placement of Shares 17
Pharmaxis Announces Second Tranche Of Private Placement Of Shares For US$20 Million 19
Boehringer Ingelheim Acquires Anti-Inflammatory Drug Candidate from Pharmaxis 20
Pharmaxis Ltd, Key Competitors 22
Pharmaxis Ltd, Key Employees 23
Pharmaxis Ltd, Subsidiaries 24

List of Figures
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharmaxis Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharmaxis Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Pharmaxis Ltd (PXS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Groupama S.A.:企業の戦略・SWOT・財務情報
    Groupama S.A. - Strategy, SWOT and Corporate Finance Report Summary Groupama S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Steven Madden Ltd (SHOO):企業の財務・戦略的SWOT分析
    Steven Madden Ltd (SHOO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Corium International Inc (CORI):医療機器:M&Aディール及び事業提携情報
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …
  • Surgical Care Affiliates LLC (SCAI):企業の財務・戦略的SWOT分析
    Summary Surgical Care Affiliates LLC (SCA), a subsidiary of UnitedHealth Group Inc is a healthcare organization that offers patient care and healthcare services. The organization's services include scheduling optimization, physician governance and engagement, case costing, profitability analysis and …
  • Western & Southern Financial Group, Inc.:戦略・SWOT・企業財務分析
    Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • The Hackett Group, Inc.:企業の戦略・SWOT・財務分析
    The Hackett Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Hackett Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • BoneSupport AB:企業の戦略的SWOT分析
    BoneSupport AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Boralex Inc (BLX):企業の財務・戦略的SWOT分析
    Boralex Inc (BLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Innovation Pharmaceuticals Inc (IPIX):医療機器:M&Aディール及び事業提携情報
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetr …
  • Kunlun Energy Co Ltd (135):企業の財務・戦略的SWOT分析
    Kunlun Energy Co Ltd (135) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Metcash Limited:企業の戦略・SWOT・財務情報
    Metcash Limited - Strategy, SWOT and Corporate Finance Report Summary Metcash Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Exelixis Inc (EXEL)-製薬・医療分野:企業M&A・提携分析
    Summary Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (c …
  • Minnetronix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Minnetronix Inc (Minnetronix) is a medical device company that offers medical system integrators. The company designs electronic and electromechanical systems. It offers products such as intraperitoneal heating and fluids control, brain stimulation system, 3-D imaging for ear canal measureme …
  • Northstar Aerospace Inc.:企業の戦略・SWOT・財務情報
    Northstar Aerospace Inc. - Strategy, SWOT and Corporate Finance Report Summary Northstar Aerospace Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Eskom Holdings SOC Limited:企業の戦略・SWOT・財務情報
    Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Emera Inc (EMA):企業の財務・戦略的SWOT分析
    Emera Inc (EMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Comtek Advanced Structures Ltd.:企業の戦略・SWOT・財務情報
    Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report Summary Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Tocagen Inc (TOCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer. The company offers lead product candidate such as Toca 511 and Toca FC, which is being investigated for the treatment of recurrent …
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆